Children with acute lymphoblastic leukemia (ALL) with у0.01% leukemic cells in the bone marrow after remission induction are at a greater risk of relapse. The most promising methods of detecting minimal residual disease (MRD) are flow cytometric identification of leukemia-associated immunophenotypes and polymerase chain reaction (PCR) amplification of antigenreceptor genes. However, neither assay can be applied to all patients. Moreover, both assays carry the risk of false-negative findings due to clonal evolution. The simultaneous use of both assays might resolve these problems, but the correlation between the methods is unknown. We studied serial 
Introduction
In the modern treatment of childhood acute lymphoblastic leukemia (ALL), the presenting biologic and clinical features of the disease are used to identify appropriate treatment intensity. 1 This strategy aims at avoiding unnecessary toxicity in patients who are at a low risk of relapse while reserving the most intensive treatment, including hemopoietic stem cell transplantation, for those with unfavorable prognostic features. However, prognostic factors currently in use are not infallible. [1] [2] [3] [4] [5] For example, approximately 10% to 15% of patients who are considered to be at low risk of treatment failure experience relapses. 1 This subset of patients may be undertreated, while others may receive chemotherapy that is more intensive and more toxic than necessary.
In children with ALL, initial response to chemotherapy is strongly associated with overall treatment outcome. [6] [7] [8] [9] Assays for minimal residual disease (MRD) can extend the usefulness of this prognostic factor by measuring the initial response to therapy in patients who have achieved complete remission by morphologic standards. The potential clinical value of these assays was conclusively demonstrated by recently reported prospective studies showing that levels of MRD during clinical remission are strongly and independently associated with treatment outcome. [10] [11] [12] These findings provide a strong rationale for the use of MRD measurements as criteria for risk assignment in childhood ALL.
Among the available methods for MRD detection in ALL, flow cytometric analysis of abnormal immunophenotypes and polymerase chain reaction (PCR) amplification of antigenreceptor genes have emerged as the most sensitive and reproducible. 13, 14 Both techniques can consistently detect 1 leukemic cell among 10 000 or more normal bone marrow mononuclear cells. [10] [11] [12] [15] [16] [17] [18] [19] [20] [21] However, neither technique can currently be applied to all patients. Further, immunophenotypic and genotypic changes during the course of the disease can cause false-negative findings. 10, 16, [22] [23] [24] [25] The simultaneous application of both assays would overcome these limitations. However, the correlation between results obtained by the two techniques is unknown. We directly compared the sensitivity and accuracy of immunologic and molecular techniques by using them to detect leukemic cells in artificial mixtures of leukemic and normal cells. We then used the methods to test 62 bone marrow samples collected from children with B-lineage ALL who were in clinical remission during therapy. The two methods provided highly concordant measurements of MRD and can therefore be used for comprehensive and reliable monitoring of MRD in childhood ALL.
Materials and methods

Cells
Bone marrow aspirates were collected in preservative-free heparin from patients with B-lineage ALL at diagnosis, at the end of remission induction (approximately 6 weeks after diagnosis; n = 60), and at weeks 6 (n = 1) and 10 (n = 1) of continuation chemotherapy. Normal peripheral blood cells were obtained from healthy volunteers. Mononuclear cells were separated by centrifugation on a density gradient (Lymphoprep; Nycomed, Oslo, Norway) and washed three times in phosphate-buffered saline. The B-lineage ALL cell line KOPN-57bi, developed in the Department of Pediatrics, Yamanashi Medical University (Yamanashi, Japan), 26 was available in our laboratory. Cells were maintained in RPMI-1640 medium (Whittaker Biotechnology, Walkersville, MD, USA) with 10% fetal calf serum, 2 mm l-glutamine and antibiotics.
Flow cytometry
Cells with leukemia-specific immunophenotypes (immunophenotypes not present in normal bone marrow cells) were investigated by multiparameter flow cytometry with various combinations of monoclonal and polyclonal antibodies against surface, cytoplasmic, or nuclear leukocyte antigens, as described. 10, 16 Antibodies were conjugated to fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein, allophycocyanine, or biotin. Isotype-matched nonreactive fluorochrome-conjugated antibodies were used as controls. The staining procedure has been described. 10, 16 For intracellular staining, cells were treated with OrthoPermeafix (Ortho Diagnostic Systems, Raritan, NJ, USA).
A FACScan or a FACScalibur flow cytometer with Cell Quest software (Becton Dickinson, San Jose, CA, USA) was used in all analyses. For each sample, we defined two gates. One surrounded the light-scatter dot plot that represented lymphoid cells, including all leukemic cells present at diagnosis in the cases studied. The other gate identified the cell population expressing the immunophenotypic features of immature lymphoid cells (eg CD19 and CD34). Electronic events falling within both gates were then selectively recorded. Acquisition was terminated when virtually all cells in the tube (2 × 10 5 or more) had passed through the flow cytometer or when 10 000 events representing immature lymphoid cells had been recorded, whichever occurred first. The expression of leukemia-specific immunophenotypes among the selected population was then analyzed. 10, 16 To identify KOPN-57bi cells admixed with normal peripheral blood cells, we labeled the mixtures with anti-CD10 conjugated to phycoerythrin and KOR-SA3544 conjugated to fluorescein isothiocyanate, two surface markers highly expressed by leukemic but not by normal cells. As many as 665 000 cells were analyzed in each test with KOPN-57bi.
PCR amplification of antigen-receptor genes
DNA samples were prepared by using the QIAamp blood kit (Qiagen, Valencia, CA, USA). IgH gene rearrangements present at diagnosis were identified by using the consensus V-region primers FR-1C 27 or FR-2B, 28 in conjunction with a universal J H primer. 29 In cases where IgH rearrangements could not be identified in the diagnostic material, we analyzed rearrangements of T cell receptor (TCR) ␥ and ␦ genes using previously described primers. 30 Reaction mixtures of 50 l contained 1 × PCR buffer (PE Applied Biosystems, Foster City, CA, USA), 100-200 ng of genomic DNA, 1.5 mm MgCl 2 , 200 m dNTPs, 0.25-0.50 m primers, and 1 unit of AmpliTaq Gold (PE Applied Biosystems). The typical amplification conditions consisted of an initial incubation for 10 min at 95°C, then 45 cycles of 30 s at 94°C and 60 s at 60°C, followed by a final incubation of 5 min at 72°C. PCR products were purified (QIAquick gel extraction kit; Qiagen) from 3% agarose gels and sequenced directly by the St Jude Center for Biotechnology (SJCBT) using dye-terminator cycle sequencing (PE Applied Biosystems). V H D H and J H regions were identified by comparison with sequences in GenBank using GCG software (Genetics Computer Group, Madison, WI, USA). For analysis of remission samples, primers complementary to the N-D-N and D-N-J nucleotides of the leukemic IgH gene rearrangement were synthesized. All primers were synthesized by the SJCBT using an ABI Model 3948 DNA synthesizer (PE Applied Biosystems) and were purified by reverse-phase chromatography (OPC cartridges; PE Applied Biosystems).
The limiting dilution method for quantifying MRD has been described previously. 21 A semi-nested PCR assay was used to detect a single copy of the leukemic gene rearrangement among 10 5 normal genomes. In the first round, 600 ng of genomic DNA was amplified for 25-30 cycles by using the FR-2B primer or a V H family consensus primer 29 with either the universal J H primer or the clone-specific D-N-J primer. For the second round, the first-round reaction mixture was diluted 1:100, and 1 l was amplified for 40-45 cycles by using the same V H family consensus primer with either the clone-specific D-N-J primer or the clone-specific N-D-N primer. PCR products were analyzed by electrophoresis on a 3% agarose gel. For every patient, both rounds of PCR were optimized to achieve the highest sensitivity and specificity. Specificity was confirmed by using pooled peripheral blood DNA and sterile water as negative controls. The sensitivity of each assay was established by making serial 10-fold dilutions of leukemic DNA with DNA prepared from pooled peripheral-blood mononuclear cells until no PCR product was observed. Equal volumes of blood from 8-10 healthy donors were used for preparation of bulk mixes of control peripheral blood DNA. MRD was quantified by limiting-dilution analysis using 10 replicates and Poisson statistics. [31] [32] [33] Between 3 × 10 5 and 1 × 10 6 genome equivalents were assayed in each patient sample; all assays could detect a single leukemic rearrangement in 10 5 genomes. To detect KOPN-57bi cells admixed with normal peripheral blood cells, we identified a rearrangement involving a V H 1 family pseudogene and the J H 6 region and amplified it as follows. The first round of PCR consisted of 30 cycles of 30 s at 94°C and 60 s at 60°C using a V H 1 family primer and the universal J H primer, with 600 ng genomic DNA in 50 l total volume. The second round consisted of 45 cycles of 20 s at 94°C, 20 s at 62°C and 20 s at 72°C, using the V H 1 primer and the KOPN-57bi-NJ primer (5Ј-GAC GTC CAT ACC GCC TTC AGA C), and 1-2 l of a 1:100 dilution of the first-round reaction mixture. All reaction mixtures contained 1 × PCR buffer (PE Applied Biosystems), 1.5 mm MgCl 2 , 200 m dNTPs, 0.25 m of each primer, and 1 U of Amplitaq Gold. Each round of PCR was preceded by an initial incubation for 10 min at 95°C and followed by incubation for 5 min at 72°C. As with patients' samples, KOPN-57bi cells were quantified by limiting dilution using 10 replicates and Poisson statistics. Ninety-five percent confidence intervals were calculated using the exact method. Figure 1b) . Nevertheless, the results of the two methods were highly concordant (r 2 = 0.962 by regression analysis; Figure 1c) . Since the PCR method that we use to measure MRD levels in patients' samples is based on the dilution of the test DNA into normal DNA, we investigated whether diluting KOPN57bi DNA with normal peripheral blood DNA would reproduce the results obtained with KOPN-57bi cells diluted with normal cells. For this purpose, we compared a 1 in 10 5 dilution for each test. At this dilution, the Poisson prediction is that 37% of replicates would yield a negative result. In both types of dilutions (cells: cells, and DNA:DNA), results were negative in three of 10 replicates (Figure 2 ), indicating that dilutions of DNA into DNA are suitable for MRD measurements.
Results
Comparison of the accuracy and sensitivity of flow cytometry and PCR in cell dilutions
Detection of MRD in remission bone marrow samples
The presence of MRD was simultaneously assessed by flow cytometry and PCR in 62 bone marrow samples taken from children with B-lineage ALL during continuation chemotherapy. At the time of sampling, all patients were considered to be in complete morphologic remission by an expert hematopathologist. Flow cytometric studies used leukemia-specific immunophenotypes identified at diagnosis, whereas the PCRbased assay used primers that specifically matched the Ig gene rearrangement of the leukemic cells at diagnosis. Flow cytometric and PCR data were recorded with no knowledge of patients' clinical status or diagnostic features, except for immunophenotype and antigen-receptor gene configuration.
Despite the absence of leukemia by morphologic criteria, 12 of the 62 samples studied contained у1 leukemic cells in 10 4 normal bone marrow mononuclear cells by both techniques. The proportion of leukemic cells in these cases ranged from 0.01% to 19% of mononuclear cells (median, 0.18%) by To determine the success of flow cytometry and PCR studies applied in tandem to monitor MRD in all children with ALL, we performed a preliminary survey of our ongoing prospective study. Since we began using both methods systematically to study MRD in consecutive patients, 52 patients with newly diagnosed ALL (13 T-lineage and 39 B-lineage) have achieved morphologic remission at the end of 6-week remission induction therapy (Table 1) . Flow cytometric studies were performed in all 13 cases with T-lineage ALL and in 29 of the 39 cases with B-lineage ALL. The remaining 10 cases did not express immunophenotypes suitable for sensitive analysis of MRD. During this time period, PCR analysis was not attempted in the T-lineage ALL cases, but it was used to monitor MRD in 35 of the 39 patients with B-lineage ALL, all of whom had IgH gene rearrangements suitable for specific and sensitive detection of MRD. Of the four remaining cases, two lacked IgH, TCR␥ and TCR␦ gene rearrangements, one lacked N regions in the rearranged IgH, TCR␥ and TCR␦ genes and 
Discussion
This study demonstrates that the two most widely used methods for MRD detection in ALL achieve remarkably concordant results. MRD findings disagreed in only two of the 62 bone marrow samples studied. In those cases, the PCR assay indicated low levels of residual disease (0.02% and 0.05%) but the flow cytometric result was negative. One possible explanation is that an immunophenotypic switch had occurred, preventing the flow cytometric identification of residual leukemic cells with the set of markers identified at the time of diagnosis. Because the two patients remain in clinical remission 9 and 13 months after the test, this possibility cannot be verified. Another possible explanation is that apoptotic leukemic cells were 'gated out' during flow cytometric analysis but still contained rearranged Ig genes amenable to PCR amplification. Re-examination of the flow cytometric plots without gating on light scatter failed to reveal obvious immunophenotypic abnormalities, but such a procedure inevitably increases background fluorescence and reduces sensitivity. Thus, the reasons for these discrepancies remain unclear.
The clinical usefulness of both techniques used in this study has been conclusively proved in large prospective trails with uniformly treated patients. [10] [11] [12] Each technique has its own relative advantages. Immunologic methods are faster and better suited to quantitative measurements, whereas PCR techniques are generally more sensitive. However, neither method can be used to study all cases. Interim analysis of our prospective study suggests that the two methods used in tandem allow comprehensive monitoring of MRD. Moreover, there are good prospects to further increase the number of patients assessable by both techniques. The use of four-color flow cytometry may increase the proportion of patients with B-lineage ALL who can be monitored by immunologic methods, 16 while the systematic use of PCR amplification of TCR receptor genes should permit molecular monitoring of most T-lineage ALL cases. [34] [35] [36] [37] [38] Technical progress may allow the study of all patients with one single method in the future, but the use of independent techniques to monitor MRD is nevertheless likely to be advan-tageous. Either method can yield false-negative results caused by phenotypic switches or by changes in antigen-receptor gene rearrangements. 10, 16, [22] [23] [24] [25] Although countermeasures can reduce the risk of false-negative findings, 16, 23, 39 immunophenotypic or genotypic evolution of relapsing leukemia continues to affect the reliability of MRD assays. In our series, discordance between the two assays was observed in only two of 62 cases. However, virtually all samples were collected within a few weeks of diagnosis, when clonal evolution was less likely to have occurred. The proportion of discordant results may be greater in samples collected at later time points. The use of two entirely independent features of leukemic cells to monitor MRD should minimize the likelihood of false-negative results. Positive findings with either assay would be considered indicative of MRD.
One prerequisite for the clinical application of MRD studies is the timely availability of results. At our institution, for example, risk-directed postremission (consolidation/ continuation) therapy begins the day after the bone marrow has been sampled for assessment of remission. Therefore, the MRD studies must be completed within 24 h. This goal is well within the reach of flow cytometric assays, which usually require only 2-3 h. To expedite the PCR studies, we characterize the antigen-receptor gene rearrangements expressed by the cells collected at diagnosis, prepare suitable primers, and optimize the PCR conditions for each case during the weeks of remission induction therapy. The remission sample can then be analyzed immediately after collection. This approach has enabled us to consistently complete MRD studies by PCR within 5-6 h, a time that could be potentially reduced by 'real-time' analysis using TaqMan technology. 40, 41 Because an average of 3 weeks was required to develop individual PCR assays (range 2-4 weeks), routine MRD investigation by PCR amplification of antigen-receptor genes does not appear to be feasible earlier than 4 weeks after diagnosis.
Improved risk classification is of the utmost importance in increasing the odds of survival for children with leukemia. 1, 3 Detection of MRD early in the course of treatment may allow therapeutic intervention to preclude the development of drug resistance. Our study shows that timely evaluation of MRD in all children with ALL is feasible. Risk classification that integrates systematic measurements of MRD with presenting clinical and biologic features of the disease should maximize the efficacy and minimize the toxicity of therapy, ultimately improving cure rates.
